PCI The Journeys Within
Media Pack
News

Current Edition

JCS - Volume 18 Issue 3 - Autumn 2026
Frankfurt 2027 – 12/10/26
ramusmedical
Regional News

J&J’s Invokana chases AZ’s Farxiga and Lilly’s Jardiance with phase 3 heart failure win

Chasing rivals from AstraZeneca and Eli Lilly/Boehringer Ingelheim, Johnson & Johnson's Invokana is vying for a piece of the lucrative heart failure market. J&am...
17 November 2021 Regional News AstraZeneca | Eli Lilly
Continue Reading →
Regional News

Pharma-backed ‘Destination Healthy Skin’ RV nears end of 2021 road tour

The Skin Cancer Foundation wanted an excuse-proof way to encourage people to get checked for melanoma and other skin cancers. So, in 2017, it launched “Destination H...
17 November 2021 Regional News dermatology | Destination Healthy Skin
Continue Reading →
Regional News

Pfizer, like Merck, inks deal to license COVID-19 pill and boost global supply

With its highly anticipated COVID-19 oral treatment seemingly on a fast track to approval, Pfizer already is lining it up to be manufactured as a generic by countries...
17 November 2021 Regional News COVID-19 | COVID-19 pill
Continue Reading →
Regional News

AbbVie’s ‘unsupported’ price hikes on Humira drove $1.4B in extra U.S. drug spending, ICER says

Over the years, the Institute for Clinical and Economic Review (ICER) has emerged as a champion in the fight against high U.S. drug costs. In its third report on unsu...
17 November 2021 Regional News AbbVie | drug cost
Continue Reading →
Regional News

Viatris launched two versions of its interchangeable insulin biosimilar. Why?

It's official: Biocon and Viatris have launched their historic interchangeable insulin biosimilar, Semglee. The drug, which references Sanofi's blockbuster diabetes m...
17 November 2021 Regional News Biocon | biosimilar
Continue Reading →
Regional News

Buffett’s Berkshire exited Merck investment just before COVID pill boost, further trimmed AbbVie and BMS holdings

Warren Buffett’s Berkshire Hathaway doesn’t appear to be the oracle of every market movement, at least not in the case of an investment in Merck & Co. The compan...
17 November 2021 Regional News COVID-19 pill | drug development
Continue Reading →
Regional News

Bristol Myers Squibb’s Opdivo posts another win in early lung cancer, but debate over treatment approach likely remains

Bristol Myers Squibb has expanded Opdivo’s first-in-class win in pre-surgery non-small cell lung cancer, teeing up a potential FDA filing. Opdivo added to chemothera...
10 November 2021 Regional News BMS | Bristol Myers Squibb
Continue Reading →
Regional News

Lilly and Boehringer’s Jardiance shows benefits for those with ‘intimately linked’ heart failure and kidney disease

Heart failure and chronic kidney disease often go hand in hand. And when they do, the risk of death and hospitalization increase. A new analysis from Eli Lilly and B...
10 November 2021 Regional News Boehringer Ingelheim | chronic kidney disease
Continue Reading →
Regional News

With Merck’s oral COVID-19 med molnupiravir set for authorization, U.S. spends another $1B for 1.4 million courses

With molnupiravir, Merck & Co. and Ridgeback’s oral treatment for COVID-19, apparently on the doorstep of authorization, the U.S. has moved to secure additional d...
10 November 2021 Regional News COVID-19 | FDA
Continue Reading →
Regional News

Biohaven taps Pfizer for global Nurtec push in deal worth up to $1.24B

Since scoring an FDA approval earlier this year to both treat and prevent migraine, Biohaven’s Nurtec ODT has jumped out ahead of Big Pharma rival AbbVie in garnering...
10 November 2021 Regional News AbbVie | Amgen
Continue Reading →
Quotient
jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2026, All Rights Reserved – Powered by Teksyte